摘要
目的评价替莫唑胺联合强放疗对恶性脑胶质瘤患者术后残留病灶近期疗效及远期生存率的影响。方法选取我院2010年1月~2013年1月收治的136例Ⅲ~Ⅳ级脑胶质瘤患者作为研究对象,手术切除术后,对照组(76例)采用单纯调强适形放射治疗,观察组(60例)采用替莫唑胺同期放化疗加替莫唑胺辅助化疗。结果观察组疾病控制率(90.00%vs.78.95%)及总有效率(73.30%vs.39.50%)均显著高于对照组,差异具有统计学意义(P<0.05)。替莫唑胺联合同步放疗后加6周期替莫唑胺辅助化疗可延长患者生存期,l、2、3年生存率分别由56.21%、24.09%、16.54%提高到75.43%、48.56%、24.87%。结论替莫唑胺联合强放疗能显著改善恶性脑胶质瘤术后残留病灶患者的近期疗效及远期生存率,并且安全性较好,在临床中有推广应用的价值。
Objective To evaluate the effects of temozolomide combined with intensive radiotherapy on short-term curative effects and long-term survival rate of patients with malignant glioma after surgery. Methods In a total, 136 patients with Ⅲ~Ⅳdegree malignant glioma were collected from our hospital between Jan. 2010 and Jan. 2013. They were randomly divided into two groups. The control group （76 cases） was treated with intensity-modulated radiotherapy （IMRT） alone after operation, and the observation group （60 cases） was treated with temozolomide combined with IMRT. Results The disease control rate （90.00% vs. 78.95%） and the total effective rate （73.30% vs.39.50%） in the observation group were significantly higher than those in the control group （P〈0.05）. Six cycles of temozolomide adjuvant chemo- therapy after synchronous treatment of temozolomide and IMRT in the observation group could prolong the survival time and increase the 1-, 2-, 3-year survival rates （56.21% vs. 75.43%, 24.09% vs. 48.56%, 16.54% vs. 24.87%, respectively）. Conclusion Temozolomide combined with IMRT can significantly improve the short-term curative effects and long-term survival rate of patients with residual glioma after sur- gery. It is safe, potential and useful for clinical application.
出处
《肿瘤药学》
CAS
2017年第2期200-203,共4页
Anti-Tumor Pharmacy
基金
内蒙古卫生厅医疗卫生科研计划项目(2010025)
关键词
恶性脑胶质瘤
替莫唑胺
放射疗法
近期疗效
远期生存率
Malignant glioma
Temozolomide
IMRT
Short-term curative effect
Long-term survival rate
